Gilead Sciences (NASDAQ:GILD) is best known for its top-selling HIV and hepatitis C drugs, but the FDA approval of Zydelig in 2014 means the company is also trying to build up its chops in cancer treatment.
So far, Zydelig has been a bit of a commercial dud, but recently reported data could change that situation if it causes Zydelig to capture a larger share of the market for recurring or relapsing chronic lymphocytic leukemia, or CLL.
Expanding access
Currently, Zydelig is only approved to treat relapsing/recurring CLL in patients who would be dosed with Rituxan alone.
